Literature DB >> 3055700

Sex steroid receptors in endometrial cancer.

J T Chambers1.   

Abstract

Endometrial cancer contains estrogen and progestin receptor proteins. The receptor content inversely correlates with histologic differentiation. The correlation between receptor content and histologic subtype and stage of the disease may depend upon the degree of differentiation of the tumor. The status of the peritoneal cytology and depth of myometrial invasion by tumor do not correlate with the receptor status. In general, patients with receptor-rich tumors have a better prognosis than those without receptors and respond favorably to progestin therapy. The level of the receptor protein in the tumor may also influence survival.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3055700      PMCID: PMC2590272     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  52 in total

1.  Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy.

Authors:  P M Martin; P H Rolland; M Gammerre; H Serment; M Toga
Journal:  Int J Cancer       Date:  1979-03-15       Impact factor: 7.396

2.  The role of progesterone in human endometrial cancer.

Authors:  R M Kelley; W H Baker
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

3.  Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors.

Authors:  G L Greene; F W Fitch; E V Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

4.  Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods.

Authors:  D G Mutch; J T Soper; D A Budwit-Novotny; E B Cox; W T Creasman; K S McCarty; K S McCarty
Journal:  Am J Obstet Gynecol       Date:  1987-10       Impact factor: 8.661

5.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.

Authors:  W A Knight; R B Livingston; E J Gregory; W L McGuire
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

6.  Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels.

Authors:  A Kauppila; O Jänne; E Kujansuu; R Vihko
Journal:  Cancer       Date:  1980-11-15       Impact factor: 6.860

7.  Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?

Authors:  T J Benraad; L G Friberg; A J Koenders; S Kullander
Journal:  Acta Obstet Gynecol Scand       Date:  1980       Impact factor: 3.636

8.  Comparison of cytosol estrogen and progestin receptor status in malignant and benign tumors and tumor-like lesions of human ovary.

Authors:  O Jänne; A Kauppila; P Syrjälä; R Vihko
Journal:  Int J Cancer       Date:  1980-02-15       Impact factor: 7.396

9.  Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma.

Authors:  K S McCarty; T K Barton; B F Fetter; W T Creasman; K S McCarty
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

10.  Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma.

Authors:  W T Creasman; K S McCarty; T K Barton; K S McCarty
Journal:  Obstet Gynecol       Date:  1980-03       Impact factor: 7.661

View more
  1 in total

Review 1.  Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors:  Y S Fu; J C Gambone; J S Berek
Journal:  West J Med       Date:  1990-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.